Prostate Cancer Medicine Market Report

Global Prostate Cancer Medicine Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：224
  • REPORT CODE：GMM838610
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Prostate Cancer Medicine market report explains the definition, types, applications, major countries, and major players of the Prostate Cancer Medicine market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Roche Holding AG

    • Abbott Laboratories

    • Teva Pharmaceuticals Industries Ltd

    • Pfizer Inc

    • Active Biotech

    • Astellas Pharma Inc

    • Bristol Myers-Squibb

    • Bayer AG

    • AstraZeneca plc

    • Johnson & Johnson

    By Type:

    • LHRH Antagonists

    • LHRH Analogs

    • Antiandrogens

    • Pipeline Drugs for Hormonal Therapy

    By End-User:

    • Hospitals

    • Clinics

    • Other

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Prostate Cancer Medicine Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Prostate Cancer Medicine Outlook to 2028- Original Forecasts

    • 2.2 Prostate Cancer Medicine Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Prostate Cancer Medicine Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Prostate Cancer Medicine Market- Recent Developments

    • 6.1 Prostate Cancer Medicine Market News and Developments

    • 6.2 Prostate Cancer Medicine Market Deals Landscape

    7 Prostate Cancer Medicine Raw Materials and Cost Structure Analysis

    • 7.1 Prostate Cancer Medicine Key Raw Materials

    • 7.2 Prostate Cancer Medicine Price Trend of Key Raw Materials

    • 7.3 Prostate Cancer Medicine Key Suppliers of Raw Materials

    • 7.4 Prostate Cancer Medicine Market Concentration Rate of Raw Materials

    • 7.5 Prostate Cancer Medicine Cost Structure Analysis

      • 7.5.1 Prostate Cancer Medicine Raw Materials Analysis

      • 7.5.2 Prostate Cancer Medicine Labor Cost Analysis

      • 7.5.3 Prostate Cancer Medicine Manufacturing Expenses Analysis

    8 Global Prostate Cancer Medicine Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Prostate Cancer Medicine Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Prostate Cancer Medicine Export by Region (Top 10 Countries) (2017-2028)

    9 Global Prostate Cancer Medicine Market Outlook by Types and Applications to 2022

    • 9.1 Global Prostate Cancer Medicine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global LHRH Antagonists Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global LHRH Analogs Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Antiandrogens Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Pipeline Drugs for Hormonal Therapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Prostate Cancer Medicine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Prostate Cancer Medicine Market Analysis and Outlook till 2022

    • 10.1 Global Prostate Cancer Medicine Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Prostate Cancer Medicine Consumption (2017-2022)

      • 10.2.2 Canada Prostate Cancer Medicine Consumption (2017-2022)

      • 10.2.3 Mexico Prostate Cancer Medicine Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.2 UK Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.3 Spain Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.4 Belgium Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.5 France Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.6 Italy Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.7 Denmark Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.8 Finland Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.9 Norway Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.10 Sweden Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.11 Poland Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.12 Russia Prostate Cancer Medicine Consumption (2017-2022)

      • 10.3.13 Turkey Prostate Cancer Medicine Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.2 Japan Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.3 India Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.4 South Korea Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.5 Pakistan Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.6 Bangladesh Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.7 Indonesia Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.8 Thailand Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.9 Singapore Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.10 Malaysia Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.11 Philippines Prostate Cancer Medicine Consumption (2017-2022)

      • 10.4.12 Vietnam Prostate Cancer Medicine Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Prostate Cancer Medicine Consumption (2017-2022)

      • 10.5.2 Colombia Prostate Cancer Medicine Consumption (2017-2022)

      • 10.5.3 Chile Prostate Cancer Medicine Consumption (2017-2022)

      • 10.5.4 Argentina Prostate Cancer Medicine Consumption (2017-2022)

      • 10.5.5 Venezuela Prostate Cancer Medicine Consumption (2017-2022)

      • 10.5.6 Peru Prostate Cancer Medicine Consumption (2017-2022)

      • 10.5.7 Puerto Rico Prostate Cancer Medicine Consumption (2017-2022)

      • 10.5.8 Ecuador Prostate Cancer Medicine Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Prostate Cancer Medicine Consumption (2017-2022)

      • 10.6.2 Kuwait Prostate Cancer Medicine Consumption (2017-2022)

      • 10.6.3 Oman Prostate Cancer Medicine Consumption (2017-2022)

      • 10.6.4 Qatar Prostate Cancer Medicine Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Prostate Cancer Medicine Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Prostate Cancer Medicine Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Prostate Cancer Medicine Consumption (2017-2022)

      • 10.7.2 South Africa Prostate Cancer Medicine Consumption (2017-2022)

      • 10.7.3 Egypt Prostate Cancer Medicine Consumption (2017-2022)

      • 10.7.4 Algeria Prostate Cancer Medicine Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Prostate Cancer Medicine Consumption (2017-2022)

      • 10.8.2 New Zealand Prostate Cancer Medicine Consumption (2017-2022)

    11 Global Prostate Cancer Medicine Competitive Analysis

    • 11.1 Roche Holding AG

      • 11.1.1 Roche Holding AG Company Details

      • 11.1.2 Roche Holding AG Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Roche Holding AG Prostate Cancer Medicine Main Business and Markets Served

      • 11.1.4 Roche Holding AG Prostate Cancer Medicine Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Abbott Laboratories

      • 11.2.1 Abbott Laboratories Company Details

      • 11.2.2 Abbott Laboratories Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Abbott Laboratories Prostate Cancer Medicine Main Business and Markets Served

      • 11.2.4 Abbott Laboratories Prostate Cancer Medicine Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Teva Pharmaceuticals Industries Ltd

      • 11.3.1 Teva Pharmaceuticals Industries Ltd Company Details

      • 11.3.2 Teva Pharmaceuticals Industries Ltd Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Teva Pharmaceuticals Industries Ltd Prostate Cancer Medicine Main Business and Markets Served

      • 11.3.4 Teva Pharmaceuticals Industries Ltd Prostate Cancer Medicine Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Pfizer Inc

      • 11.4.1 Pfizer Inc Company Details

      • 11.4.2 Pfizer Inc Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Pfizer Inc Prostate Cancer Medicine Main Business and Markets Served

      • 11.4.4 Pfizer Inc Prostate Cancer Medicine Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Active Biotech

      • 11.5.1 Active Biotech Company Details

      • 11.5.2 Active Biotech Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Active Biotech Prostate Cancer Medicine Main Business and Markets Served

      • 11.5.4 Active Biotech Prostate Cancer Medicine Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Astellas Pharma Inc

      • 11.6.1 Astellas Pharma Inc Company Details

      • 11.6.2 Astellas Pharma Inc Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Astellas Pharma Inc Prostate Cancer Medicine Main Business and Markets Served

      • 11.6.4 Astellas Pharma Inc Prostate Cancer Medicine Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Bristol Myers-Squibb

      • 11.7.1 Bristol Myers-Squibb Company Details

      • 11.7.2 Bristol Myers-Squibb Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Bristol Myers-Squibb Prostate Cancer Medicine Main Business and Markets Served

      • 11.7.4 Bristol Myers-Squibb Prostate Cancer Medicine Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Bayer AG

      • 11.8.1 Bayer AG Company Details

      • 11.8.2 Bayer AG Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Bayer AG Prostate Cancer Medicine Main Business and Markets Served

      • 11.8.4 Bayer AG Prostate Cancer Medicine Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 AstraZeneca plc

      • 11.9.1 AstraZeneca plc Company Details

      • 11.9.2 AstraZeneca plc Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 AstraZeneca plc Prostate Cancer Medicine Main Business and Markets Served

      • 11.9.4 AstraZeneca plc Prostate Cancer Medicine Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Johnson & Johnson

      • 11.10.1 Johnson & Johnson Company Details

      • 11.10.2 Johnson & Johnson Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Johnson & Johnson Prostate Cancer Medicine Main Business and Markets Served

      • 11.10.4 Johnson & Johnson Prostate Cancer Medicine Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    12 Global Prostate Cancer Medicine Market Outlook by Types and Applications to 2028

    • 12.1 Global Prostate Cancer Medicine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global LHRH Antagonists Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global LHRH Analogs Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Antiandrogens Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Pipeline Drugs for Hormonal Therapy Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Prostate Cancer Medicine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Prostate Cancer Medicine Market Analysis and Outlook to 2028

    • 13.1 Global Prostate Cancer Medicine Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.2.2 Canada Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Prostate Cancer Medicine Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.2 UK Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.3 Spain Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.5 France Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.6 Italy Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.8 Finland Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.9 Norway Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.11 Poland Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.12 Russia Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Prostate Cancer Medicine Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.2 Japan Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.3 India Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Prostate Cancer Medicine Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.5.3 Chile Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.5.6 Peru Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Prostate Cancer Medicine Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.6.3 Oman Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Prostate Cancer Medicine Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Prostate Cancer Medicine Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Prostate Cancer Medicine Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Prostate Cancer Medicine Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Prostate Cancer Medicine

    • Figure of Prostate Cancer Medicine Picture

    • Table Global Prostate Cancer Medicine Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Prostate Cancer Medicine Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global LHRH Antagonists Consumption and Growth Rate (2017-2022)

    • Figure Global LHRH Analogs Consumption and Growth Rate (2017-2022)

    • Figure Global Antiandrogens Consumption and Growth Rate (2017-2022)

    • Figure Global Pipeline Drugs for Hormonal Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Prostate Cancer Medicine Consumption by Country (2017-2022)

    • Table North America Prostate Cancer Medicine Consumption by Country (2017-2022)

    • Figure United States Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Canada Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Mexico Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Table Europe Prostate Cancer Medicine Consumption by Country (2017-2022)

    • Figure Germany Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure UK Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Spain Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Belgium Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure France Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Italy Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Denmark Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Finland Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Norway Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Sweden Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Poland Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Russia Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Turkey Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Table APAC Prostate Cancer Medicine Consumption by Country (2017-2022)

    • Figure China Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Japan Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure India Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure South Korea Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Thailand Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Singapore Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Philippines Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Table South America Prostate Cancer Medicine Consumption by Country (2017-2022)

    • Figure Brazil Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Colombia Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Chile Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Argentina Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Peru Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Table GCC Prostate Cancer Medicine Consumption by Country (2017-2022)

    • Figure Bahrain Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Oman Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Qatar Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Table Africa Prostate Cancer Medicine Consumption by Country (2017-2022)

    • Figure Nigeria Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure South Africa Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Egypt Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure Algeria Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Table Oceania Prostate Cancer Medicine Consumption by Country (2017-2022)

    • Figure Australia Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Prostate Cancer Medicine Consumption and Growth Rate (2017-2022)

    • Table Roche Holding AG Company Details

    • Table Roche Holding AG Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Holding AG Prostate Cancer Medicine Main Business and Markets Served

    • Table Roche Holding AG Prostate Cancer Medicine Product Portfolio

    • Table Abbott Laboratories Company Details

    • Table Abbott Laboratories Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott Laboratories Prostate Cancer Medicine Main Business and Markets Served

    • Table Abbott Laboratories Prostate Cancer Medicine Product Portfolio

    • Table Teva Pharmaceuticals Industries Ltd Company Details

    • Table Teva Pharmaceuticals Industries Ltd Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceuticals Industries Ltd Prostate Cancer Medicine Main Business and Markets Served

    • Table Teva Pharmaceuticals Industries Ltd Prostate Cancer Medicine Product Portfolio

    • Table Pfizer Inc Company Details

    • Table Pfizer Inc Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Prostate Cancer Medicine Main Business and Markets Served

    • Table Pfizer Inc Prostate Cancer Medicine Product Portfolio

    • Table Active Biotech Company Details

    • Table Active Biotech Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Active Biotech Prostate Cancer Medicine Main Business and Markets Served

    • Table Active Biotech Prostate Cancer Medicine Product Portfolio

    • Table Astellas Pharma Inc Company Details

    • Table Astellas Pharma Inc Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Inc Prostate Cancer Medicine Main Business and Markets Served

    • Table Astellas Pharma Inc Prostate Cancer Medicine Product Portfolio

    • Table Bristol Myers-Squibb Company Details

    • Table Bristol Myers-Squibb Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol Myers-Squibb Prostate Cancer Medicine Main Business and Markets Served

    • Table Bristol Myers-Squibb Prostate Cancer Medicine Product Portfolio

    • Table Bayer AG Company Details

    • Table Bayer AG Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer AG Prostate Cancer Medicine Main Business and Markets Served

    • Table Bayer AG Prostate Cancer Medicine Product Portfolio

    • Table AstraZeneca plc Company Details

    • Table AstraZeneca plc Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca plc Prostate Cancer Medicine Main Business and Markets Served

    • Table AstraZeneca plc Prostate Cancer Medicine Product Portfolio

    • Table Johnson & Johnson Company Details

    • Table Johnson & Johnson Prostate Cancer Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Prostate Cancer Medicine Main Business and Markets Served

    • Table Johnson & Johnson Prostate Cancer Medicine Product Portfolio

    • Figure Global LHRH Antagonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global LHRH Analogs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Antiandrogens Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pipeline Drugs for Hormonal Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prostate Cancer Medicine Consumption Forecast by Country (2022-2028)

    • Table North America Prostate Cancer Medicine Consumption Forecast by Country (2022-2028)

    • Figure United States Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Prostate Cancer Medicine Consumption Forecast by Country (2022-2028)

    • Figure Germany Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Prostate Cancer Medicine Consumption Forecast by Country (2022-2028)

    • Figure China Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Prostate Cancer Medicine Consumption Forecast by Country (2022-2028)

    • Figure Brazil Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Prostate Cancer Medicine Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Prostate Cancer Medicine Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Prostate Cancer Medicine Consumption Forecast by Country (2022-2028)

    • Figure Australia Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Prostate Cancer Medicine Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US